Targazyme Stock

targazyme.comHealthcareFounded: 2005Funding to Date: $2.5MM

Targazyme is a clinical-stage biopharmaceutical company developing novel enzyme-based platform technologies and products to improve clinical efficacy and cost of care outcomes for cell therapy, immunotherapies for autoimmune diseases and cancer, stem cell transplantation, gene therapy and regenerative medicine.

Register for Details

For more details on financing and valuation for Targazyme, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Targazyme.

Register Today

Team

Management Team

Stephen Wolpe Ph.D
Chief Scientific Officer
Zhongling Feng MD
Associate Chief Medical Officer
Bernard Cambou
Chief Business Officer
Lynnet Koh
Chief Executive Officer, President, Chairman & Co-Founder
Lynne Bui MD
Chief Medical Officer & Senior Vice President, Development

Board Members

Kris Narayan
Targazyme
Mark Schwartz Ph.D
Targazyme
Charles Levine
Targazyme
Christopher Calhoun
Targazyme
Michael LeMaire
Alan Lewis Ph.D
Lynnet Koh
Targazyme

Other companies like Targazyme in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$317.32MM
Sector
 
 
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$334.19MM